CIK 0000899923 · Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 870494517
- Phone
- 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 4 Grant or award Chief Operating Officer acquired 1,118 shares (grant or award)
- 8-K Event Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale President and CEO sold 15,000 shares at $22.93 ($343,950)
- 144 Insider Sale of Securities
- 4 Shares withheld for taxes Chief Commercial Officer gave up 8,363 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 452 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technology Officer gave up 2,515 shares (to pay taxes)
- 8-K Event Results of operations
- 4 Shares withheld for taxes Chief Commercial Officer gave up 1,075 shares (to pay taxes)
- 4 Shares withheld for taxes SVP, Chief of Staff gave up 966 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Accounting Officer gave up 964 shares (to pay taxes)
- 144 Insider Sale of Securities
- 4 Planned sale President and CEO sold 15,000 shares at $26.72 ($400,800)
- 4 Open-market sale Chief Scientific Officer sold 2,100 shares at $26.17 ($54,961)
- 144 Insider Sale of Securities
Page 10 of 104 · 2,077 filings